BlossomHill Therapeutics earnings release, September 18, 2026

BlossomHill Therapeutics, Inc. (BLSM) · Form 8-K, Item 2.02 · Filed · SEC filing

BlossomHill Therapeutics Reports Second Quarter 2026 Financial Results

Strengthened balance sheet with successful completion of upsized $168.3 million initial public offering

Announced FDA Fast Track designation for

BH-30643 for the treatment of advanced

EGFR C797S-positive NSCLC

SAN DIEGO,

September 18, 2026 – BlossomHill

Therapeutics, Inc.

(Nasdaq: BLSM), a clinical-stage biopharmaceutical company applying an intentional, chemistry-based approach to design and develop innovative small molecule medicines for the treatment of cancer, today announced financial results for the second quarter 2026 and highlighted recent progress.

“We’ve achieved meaningful progress across our pipeline, as well as our significant corporate milestones, since the beginning of the second quarter,” said Jean Cui, Ph.D., Founder, President and Chief Executive Officer of BlossomHill Therapeutics. “In April, we presented our first preclinical data from our pseudo-irreversible pan-KRAS inhibitor

BH-501284, built on a novel chemical scaffold, at AACR where we highlighted the sustained target engagement leading to tumor regression at low dose levels. At ASCO in early June we presented the preliminary safety, PK and antitumor activities of

BH-30643 in Phase 1 dose escalation of the SOLARA trial, along with the initial efficacy data in C797S-positive NSCLC. More recently we announced that

BH-30643 received Fast Track designation, an important regulatory milestone that reflects the FDA’s recognition of the potential for this molecule. We also presented encouraging safety data and early signs of anti-leukemic activity observed with

BH-30236, our novel macrocyclic CLK inhibitor, both as a monotherapy and in combination with venetoclax, at EHA in the middle of June. We are now looking forward to our end-of-phase

1 meeting with the FDA later this year. With a strong balance sheet following our successful initial public offering in August, we believe we are well positioned to deliver important clinical and regulatory milestones over the coming quarters as we continue advancing our intentionally designed medicines that address significant unmet medical needs in cancer treatment.”

Recent Business Highlights and Corporate Updates:

Anticipated Upcoming Milestones:

BH-30643

BH-501284

BH-30236

Second Quarter 2026 Financial Results

Research and development (R&D) expenses for the second quarter of 2026 were $21.4 million, compared with $12.5 million for the same period in 2025. The increase was primarily due to greater clinical development expenses driven by the SOLARA trial, expenses to support

IND-enabling studies for

BH-501284, and greater costs related to personnel, facilities and other overhead.

General and administrative (G&A) expenses for the second quarter of 2026 were $3.3 million, compared with $1.6 million for the same period in 2025. The increase was primarily due to greater legal expenses, personnel-related expenses and overhead.

Net loss for the second quarter of 2026 was $23.8 million, or $(8.75) per basic and diluted share, compared with a net loss of $13.2 million, or $(5.51) per basic and diluted share for the same period in 2025. The increase in net loss was primarily attributable to increased operating expenses.

Cash and cash equivalents totaled

$95.4 million as of June 30, 2026. BlossomHill subsequently completed its IPO in August 2026 in which it sold 10,516,240 shares of its common stock, including partial exercise of the over-allotment option, for gross proceeds of

$168.3 million. BlossomHill believes that its cash and cash equivalents as of June 30, 2026, together with the proceeds from its IPO, will be sufficient to fund its operations into the second quarter of 2028.

About

BH-30643

BH-30643 is an investigational, novel, orally bioavailable, non-covalent, macrocyclic, brain active, mutant-selective, OMNI-EGFR™ inhibitor for the treatment of

EGFR

-mutant NSCLC.

BH-30643 was designed to overcome the limitations of currently approved EGFR inhibitors, which were discovered over a decade ago without the current, modern understanding of the structure and protein dynamics of mutant EGFRs. In preclinical studies,

BH-30643 demonstrated potent inhibitory activity across diverse

EGFR mutation categories – classical mutations, on-target resistance mutations such as C797S with or without T790M, atypical mutations and exon 20 insertions – while maintaining marked selectivity over wild-type EGFR.

BH-30643 has received Fast Track designation and is being evaluated in SOLARA, a global Phase 1/2, first-in-human clinical trial spanning more than 40 sites in 10 countries. Ongoing dose expansion cohorts are enrolling in both

TKI-pretreated and

TKI-naive settings, including a C797S resistance cohort. For additional information on SOLARA, including a list of study sites and how to enroll, please visit clinicaltrials.gov (

NCT06706076).

About

BH-30236

BH-30236 is an investigational orally bioavailable, macrocyclic inhibitor of the

CDC-like kinase (CLK) family.

BH-30236 was intentionally designed to potently inhibit CLK, leading to modulation of aberrant alternative splicing in cancerous tissue, targeting the same aberrant splicing machinery that drives relapsed or refractory (R/R) acute myeloid leukemia (AML) and higher-risk myelodysplastic syndromes

(HR-MDS) disease biology and that cancer cells exploit to develop resistance to venetoclax, FLT3 inhibitors and cytarabine.

BH-30236 is being evaluated in a Phase 1/1b multicenter, open-label, first-in-human dose escalation and expansion trial in adults with R/R AML and

HR-MDS.

The U.S. Food and Drug Administration (FDA) has granted orphan drug designation to

BH-30236 for the treatment of AML. For additional information... (truncated)o enroll, please visit clinicaltrials.gov (

NCT06501196).

About

BH-501284

BH-501284 is an investigational, orally bioavailable pan-KRAS inhibitor, which utilizes a novel

Switch-II chemical scaffold to achieve prolonged, potent and selective inhibition of KRAS mutations. We believe this molecule, which uses a non-covalent scaffold, is unique in its potential to achieve tight and durable binding, a feature described as “pseudo-irreversible” binding. In preclinical studies,

BH-501284 has achieved pseudo-irreversible binding characteristics with high binding affinity, while maintaining high selectivity for KRAS.

About BlossomHill Therapeutics

BlossomHill Therapeutics, Inc. is a clinical-stage biopharmaceutical company applying an intentional, chemistry-based approach to design and develop innovative small molecule medicines that address significant unmet medical needs in cancer treatment. Founded and led by industry veteran J. Jean Cui, Ph.D., with her proven track record in oncology drug design and development – including three

FDA-approved drugs – BlossomHill Therapeutics applies cutting-edge science with a goal to address key oncogenic drivers and improve patient outcomes in difficult-to-treat cancers. The company’s lead clinical program is

BH-30643, an investigational, non-covalent, macrocyclic, brain active, mutant-selective OMNI-EGFR

TM inhibitor for the treatment of EGFR-mutant non-small cell lung cancer (NSCLC), which has received

Fast Track designation for the C797S resistance population after 3rd generation EGFR TKI treatment. The company is also conducting clinical development of

BH-30236, an investigational macrocyclic

CDC-like kinase (CLK) inhibitor initially being studied in a clinical trial for the treatment of relapsed or refractory acute myeloid leukemia (R/R AML) and higher-risk myelodysplastic syndromes

(HR-MDS).

The company’s pipeline also includes

BH-501284, a preclinical, non-covalent, selective, pan-KRAS

Switch-II inhibitor for potential future development in diverse KRAS-mutant tumors.

BlossomHill Therapeutics is headquartered in San Diego, California. For more information, visit bhtherapeutics.com and follow us on

LinkedIn and

X.

Cautionary Note Regarding Forward-Looking

Statements

Financial statements

Income Statement

Three Months Ended June 30, — (in thousands, except share and per share data)

Three Months Ended June 30, – 2026Three Months Ended June 30, – 2025Six Months Ended June 30, – 2026Six Months Ended June 30, – 2025
Operating expenses:Research and development21,35512,53041,25622,102
Operating expenses:General and administrative3,3151,5735,5213,455
Operating expenses:Total operating expenses24,67014,10346,77725,557
Operating expenses:Loss from operations-24,670-14,103-46,777-25,557
Other income (expense), net:Interest income, net9158592,0171,835
Other income (expense), net:Other expense, net-3-6
Other income (expense), net:Total other income, net9128592,0111,835
Other income (expense), net:Net loss-23,758-13,244-44,766-23,722
Other income (expense), net:Net loss per share, basic and diluted-8.75-5.51-16.91-9.9
Other income (expense), net:Weighted average common shares outstanding, basic and diluted2,713,6962,405,1402,646,7212,395,789

Balance Sheet

June 30, 2026 — (in thousands, except share and par value data)

June 30, 2026 – (unaudited)December 31, 2025
Current Assets:Cash and cash equivalents95,376136,682
Current Assets:Prepaid expenses and other current assets5,5922,144
Current Assets:Total current assets100,968138,826
Current Assets:Property and equipment, net1,4891,726
Current Assets:Operating lease right-of-use assets19,19719,921
Current Assets:Other assets2,4772,495
Current Assets:Total assets124,131162,968
Current liabilities:Accounts payable3,9302,314
Current liabilities:Accrued expenses9,1948,431
Current liabilities:Accrued compensation3,5394,730
Current liabilities:Other current liabilities809
Current liabilities:Operating lease liability, current1,1495
Current liabilities:Total current liabilities18,62115,480
Current liabilities:Operating lease liability, non-current22,22222,393
Current liabilities:Other long-term liabilities1,245
Current liabilities:Total liabilities42,08837,873
Current liabilities:Convertible preferred stock, $0.0001 par value; 85,552,612 shares authorized at June 30, 2026 and December 31, 2025; 18,258,960 shares issued and outstanding at June 30, 2026 and December 31, 2025; $257,153 aggregate liquidation preference at June 30, 2026 and December 31, 2025256,823256,823
Stockholders’ deficit:Common stock, $0.0001 par value; 110,000,000 shares authorized at June 30, 2026 and December 31, 2025; 2,767,848 and 2,548,659 shares issued and outstanding as of June 30, 2026 and December 31, 2025, respectively11
Stockholders’ deficit:Additional paid-in capital5,0143,300
Stockholders’ deficit:Accumulated deficit-179,795-135,029
Stockholders’ deficit:Total stockholders’ deficit-174,780-131,728
Stockholders’ deficit:Total liabilities, convertible preferred stock and stockholders’ deficit124,131162,968
Full release

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, and other federal securities laws, including, without limitation, statements regarding: the therapeutic potential, clinical benefits, safety and potential competitive differentiation of the company’s product candidates, including

BH-30643,

BH-30236 and

BH-501284; the anticipated benefits of regulatory designations received, or that may be received, by the company’s product candidates; the design, enrollment, timing, progress and results of the company’s clinical trials and preclinical studies; the company’s planned regulatory interactions and submissions; anticipated program milestones, including the timing of program and data updates; the period over which the company estimates its existing cash and cash equivalents, together with the net proceeds from its initial public offering, will be sufficient to fund its current operating plan; statements by the company’s management; and the company’s development plans and continued advancement of its pipeline. The words “anticipate,” “believe,” “could,”

“estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “upcoming,”

“will,” “would” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words.

Any forward-looking statements in this press release are based on management’s current expectations and beliefs and are subject to a number of risks, uncertainties and important factors that may cause actual events or results to differ materially, including, without limitation: the company’s limited operating history, history of significant losses and the early stage of development of its product candidates; the risk that preliminary and interim clinical data are subject to further analysis and may not be predictive of, may be inconsistent with, or may be more favorable than, data generated as clinical trials continue or data from future clinical trials; uncertainties inherent in the initiation, timing, design and enrollment of clinical trials, and the availability and timing of data from ongoing and future trials; the company’s ability to successfully demonstrate the safety and efficacy of its product candidates and to obtain and maintain regulatory approvals; the timing and outcome of planned interactions with, and submissions to, the FDA and other regulatory authorities, including whether an accelerated approval pathway will be available to the company; the risk that regulatory designations, including Fast Track and orphan drug designation, may not result in a faster development, review or approval process, may not increase the likelihood of regulatory approval, and may be withdrawn; competition from third parties that are developing products for similar indications; the prior success of the company’s management team may not be indicative of future success; the company’s reliance on third parties, including contract research organizations and contract manufacturing organizations; the company’s ability to obtain, maintain and protect its intellectual property; and the company’s need for additional financing and its estimates regarding operating expenses and capital requirements. These and other risks are described in greater detail under the heading “Risk Factors” in the company’s filings with the Securities and Exchange

Commission (the “SEC”), its Quarterly Report on Form

10-Q... (truncated)ent filings with the SEC. Any forward-looking statements represent the company’s views only as of the date of this press release, and the company expressly disclaims any obligation to update any forward-looking statements, except as required by law.

Company Contact:

Michael Moore, BlossomHill Therapeutics michael.moore@bhtherapeutics.com

Media:

Ashlea Kosikowski, 1AB ashlea@1abmedia.com

From SEC EDGAR. Analysis by Pear Digitals from the filing alone. Not investment advice. · BlossomHill Therapeutics earnings · Latest earnings · Markdown

Screener

Plans

Premium and Pro coming soon.

Log in

New here?

Join the waitlist

Pear FMV opens to everyone soon. We'll email you when it does.